Vivos Therapeutics (VVOS) Competitors $4.61 0.00 (0.00%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$4.32 -0.30 (-6.40%) As of 08/14/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VVOS vs. ZJYL, FONR, HYPR, NVNO, APYX, VANI, NTRB, TELA, LUNG, and SPAIShould you be buying Vivos Therapeutics stock or one of its competitors? The main competitors of Vivos Therapeutics include Jin Medical International (ZJYL), Fonar (FONR), Hyperfine (HYPR), enVVeno Medical (NVNO), Apyx Medical (APYX), Vivani Medical (VANI), Nutriband (NTRB), TELA Bio (TELA), Pulmonx (LUNG), and Safe Pro Group (SPAI). These companies are all part of the "medical equipment" industry. Vivos Therapeutics vs. Its Competitors Jin Medical International Fonar Hyperfine enVVeno Medical Apyx Medical Vivani Medical Nutriband TELA Bio Pulmonx Safe Pro Group Jin Medical International (NASDAQ:ZJYL) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Which has more volatility & risk, ZJYL or VVOS? Jin Medical International has a beta of 9.79, meaning that its share price is 879% more volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.03, meaning that its share price is 603% more volatile than the S&P 500. Which has higher valuation and earnings, ZJYL or VVOS? Jin Medical International has higher revenue and earnings than Vivos Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJin Medical International$23.50M4.21$3.68MN/AN/AVivos Therapeutics$15.03M1.81-$11.14M-$1.73-2.66 Is ZJYL or VVOS more profitable? Jin Medical International has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -76.82%. Jin Medical International's return on equity of 0.00% beat Vivos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Jin Medical InternationalN/A N/A N/A Vivos Therapeutics -76.82%-170.43%-77.82% Do insiders and institutionals hold more shares of ZJYL or VVOS? 26.4% of Vivos Therapeutics shares are owned by institutional investors. 3.0% of Vivos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer ZJYL or VVOS? Vivos Therapeutics has a consensus price target of $4.82, suggesting a potential upside of 4.48%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Vivos Therapeutics is more favorable than Jin Medical International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jin Medical International 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vivos Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to ZJYL or VVOS? In the previous week, Vivos Therapeutics had 2 more articles in the media than Jin Medical International. MarketBeat recorded 4 mentions for Vivos Therapeutics and 2 mentions for Jin Medical International. Jin Medical International's average media sentiment score of 1.58 beat Vivos Therapeutics' score of 0.51 indicating that Jin Medical International is being referred to more favorably in the media. Company Overall Sentiment Jin Medical International Very Positive Vivos Therapeutics Positive SummaryJin Medical International beats Vivos Therapeutics on 8 of the 14 factors compared between the two stocks. Get Vivos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VVOS vs. The Competition Export to ExcelMetricVivos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.15M$2.48B$5.61B$9.84BDividend YieldN/A1.76%4.61%4.07%P/E Ratio-2.6622.0530.2825.74Price / Sales1.81742.42460.47115.79Price / CashN/A184.4138.2159.48Price / Book3.414.838.856.15Net Income-$11.14M$31.61M$3.25B$265.06M7 Day Performance4.77%4.55%3.72%2.60%1 Month Performance-31.60%5.69%5.86%2.83%1 Year Performance106.73%12.71%30.34%25.58% Vivos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VVOSVivos Therapeutics0.8711 of 5 stars$4.61flat$4.82+4.5%+94.5%$27.15M$15.03M-2.66160News CoverageGap DownZJYLJin Medical InternationalN/A$0.65-1.2%N/A-81.7%$103.01M$23.50M0.00245News CoveragePositive NewsShort Interest ↓FONRFonar2.466 of 5 stars$15.20-1.4%N/A-9.4%$95.60M$102.88M12.16480News CoverageHYPRHyperfine1.8717 of 5 stars$1.30+12.1%$1.06-18.5%+38.1%$90.29M$12.89M-2.41190Trending NewsEarnings ReportAnalyst ForecastNVNOenVVeno Medical0.8561 of 5 stars$4.52-2.6%N/A-13.6%$89.31MN/A-3.7730APYXApyx Medical1.8527 of 5 stars$2.23+2.3%N/A+79.7%$82.45M$48.10M-4.96270VANIVivani Medical2.6509 of 5 stars$1.26-8.7%$4.00+217.5%+0.8%$81.76MN/A-2.9320News CoverageEarnings ReportNTRBNutriband3.2538 of 5 stars$6.85-4.5%$13.00+89.8%+5.5%$79.97M$2.14M-7.6110Short Interest ↓TELATELA Bio2.7364 of 5 stars$1.86+8.1%$7.25+289.8%-47.2%$68.04M$69.30M-1.32120Earnings ReportGap UpHigh Trading VolumeLUNGPulmonx4.2722 of 5 stars$1.55flat$7.66+394.5%-73.6%$63.16M$83.79M-1.08250SPAISafe Pro Group0.8857 of 5 stars$3.86-6.8%$8.00+107.3%N/A$62.81M$2.17M-4.7711Earnings Report Related Companies and Tools Related Companies Jin Medical International Competitors Fonar Competitors Hyperfine Competitors enVVeno Medical Competitors Apyx Medical Competitors Vivani Medical Competitors Nutriband Competitors TELA Bio Competitors Pulmonx Competitors Safe Pro Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VVOS) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access